VanEck Associates’s VanEck Biotech ETF BBH Stock Holding History

VanEck Associates’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-13	Closed	-$2K	–	1391
2024 Q3	$2K	Sell	13 -1	-7%	-$177	﹤0.01%	1368
2024 Q2	$2K	Sell	14 -7	-33%	-$1.15K	﹤0.01%	1363
2024 Q1	$3K	Hold	21	–	–	﹤0.01%	1354
2023 Q4	$3K	Hold	21	–	–	﹤0.01%	1375
2023 Q3	$3K	Hold	21	–	–	﹤0.01%	1385
2023 Q2	$3K	Hold	21	–	–	﹤0.01%	1390
2023 Q1	$3K	Buy	21 +2	+11%	+$324	﹤0.01%	1400
2022 Q4	$3K	Hold	19	–	–	﹤0.01%	1407
2022 Q3	$3K	Hold	19	–	–	﹤0.01%	1360
2022 Q2	$3K	Hold	19	–	–	﹤0.01%	1342
2022 Q1	$3K	Hold	19	–	–	﹤0.01%	1338
2021 Q4	$4K	Buy	+19	New	+$3.66K	﹤0.01%	1341

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

VanEck Associates's BBH Position: Q4 2024 in Review

VanEck Associates sold out of VanEck Biotech ETF (BBH) in Q4 2024, closing a stake of 13 shares — an estimated $2K sold.

VanEck Associates first reported a position in BBH in Q4 2021 and held it in 12 quarters. The position peaked at $4K in Q4 2021. 115 funds tracked by Wall St. Rank hold BBH as of Q4 2024.

VanEck Associates reported no remaining VanEck Biotech ETF position as of Q4 2024 after selling out during the quarter.
VanEck Associates sold 13 VanEck Biotech ETF shares in Q4 2024, an estimated $2K.
VanEck Associates first reported a position in VanEck Biotech ETF in Q4 2021 and held it in 12 quarters.
VanEck Associates's VanEck Biotech ETF position peaked at $4K in Q4 2021.
115 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q4 2024.

Based on VanEck Associates's 13F filing for Q4 2024, filed 29 Jan 2025.